Patents Assigned to Protgen Ltd.
-
Publication number: 20240165140Abstract: A method for treating a tumor or cancer by means of a treatment scheme of using endostatin in combination with induction of DNA double-strand breaks, and a medication. The method and composition are used for treating a tumor or cancer related to loss of p53 function, or a tumor or cancer occurring when p53 function is normal.Type: ApplicationFiled: November 17, 2023Publication date: May 23, 2024Applicants: TSINGHUA UNIVERSITY, BEIJING PROTGEN LTD.Inventors: Yongzhang LUO, Lin JIA, Guodong CHANG
-
Publication number: 20230390364Abstract: Provided is the use of human serum albumin in the manufacturing of a drug for treating diabetes, obesity, atherosclerosis, Alzheimer's disease, Parkinson's disease and other diseases. In a preferred embodiment, the human serum albumin is the recombinantly prepared young and uninjured human serum albumin, and has achieved excellent effects in reducing the blood sugar level of a diabetic patient.Type: ApplicationFiled: November 1, 2021Publication date: December 7, 2023Applicant: Shenzhen Protgen Ltd.Inventors: Yongzhang Luo, Yan Fu, Hongyi Liu, Anji Ju, Jiaze Tang, Yi Jiang, Boyuan Ma, Xiaoqin Jiang, Yu Feng, Guodong Chang, Hui Li
-
Patent number: 11098104Abstract: The present invention provides a polyethylene glycol-modified endostatin analogue and an application thereof. The endostatin analogue is coupled to polyethylene glycol at lysine away from a nucleolin binding domain, or is coupled to polyethylene glycol at lysine away from a nucleolin binding domain and amidogen at the N end.Type: GrantFiled: November 10, 2017Date of Patent: August 24, 2021Assignee: BEIJING PROTGEN LTD.Inventors: Daifu Zhou, Wenchao Wang, Hui Li, Guodong Chang
-
Publication number: 20210085754Abstract: Provided is a mutant of an endostatin. The mutant has improved ATPase activity and improved activity of inhibiting angiogenesis and inhibiting tumors. Further provided is use of the mutant in treatment of angiogenesis related diseases such as tumors.Type: ApplicationFiled: September 28, 2020Publication date: March 25, 2021Applicants: TSINGHUA UNIVERSITY, BEIJING PROTGEN LTD.Inventors: Yongzhang LUO, Peng LIU, Xinan LU
-
Patent number: 10869910Abstract: Provided is a mutant of an endostatin. The mutant has improved ATPase activity and improved activity of inhibiting angiogenesis and inhibiting tumors. Further provided is use of the mutant in treatment of angiogenesis related diseases such as tumors.Type: GrantFiled: February 14, 2016Date of Patent: December 22, 2020Assignees: Tsinghua University, BEIJING PROTGEN LTD.Inventors: Yongzhang Luo, Peng Liu, Xinan Lu
-
Publication number: 20200270333Abstract: The present invention provides a polyethylene glycol-modified endostatin analogue and an application thereof. The endostatin analogue is coupled to polyethylene glycol at lysine away from a nucleolin binding domain, or is coupled to polyethylene glycol at lysine away from a nucleolin binding domain and amidogen at the N end.Type: ApplicationFiled: November 10, 2017Publication date: August 27, 2020Applicant: BEIJING PROTGEN LTD.Inventors: Daifu Zhou, Wenchao Wang, Hui Li, Guodong Chang
-
Patent number: 10647968Abstract: The present invention discloses a new anti-tumor medicament comprising a mutant of endostatin. The mutant comprises a mutation in the ATP-binding site of endostatin and has a decreased ATPase activity and an increased anti-angiogenesis activity.Type: GrantFiled: September 10, 2012Date of Patent: May 12, 2020Assignees: Tsinghua University, Beijing Protgen Ltd.Inventors: Yongzhang Luo, Peng Liu, Xinan Lu, Yang Chen, Yan Fu, Guodong Chang, Daifu Zhou
-
Publication number: 20190330707Abstract: Provided is a method for the high expression of a recombinant human serum albumin, characterized in comprising the step of co-expressing: (a) a human serum albumin gene, and (b) one or more rHSA expression promoting factor genes in a yeast host cell.Type: ApplicationFiled: May 4, 2017Publication date: October 31, 2019Applicant: Shenzhen Protgen Ltd.Inventors: Guodong Chang, Xin Dou, Xiaobo Xiong, Wenchao Wang
-
Publication number: 20180360922Abstract: The present invention discloses an anti-tumor conjugate and pharmaceutical composition or kits comprising the conjugate, as well as a method of producing the anti-tumor conjugate. The anti-tumor conjugate of the present invention is metabolically stable in vivo, and is ultimately available for the treatment of tumors and production of anti-tumor medicaments.Type: ApplicationFiled: July 2, 2018Publication date: December 20, 2018Applicants: TSINGHUA UNIVERSITY, PROTGEN LTD.Inventors: Yongzhang LUO, Qing HAN, Qingxin LEI, Guodong CHANG, Yan FU
-
Patent number: 10054590Abstract: The present invention relates to a method of identifying cancer subjects, in particular human patients, who are suitable for anti-lymphangiogenesis therapy to prevent tumor growth and tumor metastasis. The present invention also relates to a new approach, which uses nucleolin as a bait to search and screen for lymphangiogenesis inhibitors or cancer suppressors, which function in a manner that is analogous to endostatin. The invention is based upon the discovery that nucleolin is specifically expressed on lymphangiogenic vessels and functions as a specific receptor for endostatin, and thus is involved in the signal transduction pathway of endostatin as an anti-lymphangiogenesis inhibitor. The present invention also discloses that cell surface nucleolin on lymphatic endothelial cells is a biomarker for lymphangiogenic vessels, which could be used for the prediction of tumor metastasis.Type: GrantFiled: August 8, 2013Date of Patent: August 21, 2018Assignees: Tsinghua University, Protgen Ltd.Inventors: Yongzhang Luo, Wei Zhuo, Yan Fu, Guodong Chang
-
Publication number: 20180200337Abstract: Provided is amutant of an endostatin. The mutant has improved ATPase activity and improved activity of inhibiting angiogenesis and inhibiting tumors. Further provided is use of the mutant in treatment of angiogenesis related diseases such as tumors.Type: ApplicationFiled: February 14, 2016Publication date: July 19, 2018Applicants: Tsinghua University, BEIJING PROTGEN LTD.Inventors: Yongzhang LUO, Peng LIU, Xinan LU
-
Publication number: 20180015148Abstract: The present invention provides use of endostatin or a functional variant thereof in the preparation of a medicament for treating dietary obesity, non-alcoholic fatty liver disease, insulin resistance or glucose intolerance. In the embodiments of the present invention, the functional variant may be YH-16, mES, mYH-16, m003, m007, mZ101, or the like.Type: ApplicationFiled: November 3, 2015Publication date: January 18, 2018Applicants: TSINGHUA UNIVERSITY, BEIJING PROTGEN LTD.Inventors: Yongzhang LUO, Hui WANG, Hui LI, Xinan LU, Yan FU, Shunli ZHAN, Daifu ZHOU
-
Patent number: 9815906Abstract: The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence, status or metastasis of cancer by detecting plasma Hsp90? having the amino acid sequence of SEQ ID NO:1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.Type: GrantFiled: February 13, 2015Date of Patent: November 14, 2017Assignees: TSINGHUA UNIVERSITY, PROTGEN LTD.Inventors: Yongzhang Luo, Xiaomin Song, Xiaofeng Wang, Wei Zhuo, Guodong Chang, Yan Fu
-
Publication number: 20160178633Abstract: A method of determining whether a subject has cancer or has a risk of getting cancer comprises: detecting the concentration of Hsp90a in a blood sample of the subject; and if the concentration reaches or exceeds a preset threshold value, determining that the subject has cancer or has a risk of getting cancer, where the threshold value is selected from a range from 50 ng/ml to 120 ng/ml; for example, the threshold value may be 50, 53, 56, 62, 63, 64, 67, 72, 82, 85 or 117 ng/ml, and a numerical value within the ±15% range of the threshold value is regarded having equivalent significance for determination.Type: ApplicationFiled: June 27, 2014Publication date: June 23, 2016Applicants: TSINGHUA UNIVERSITY, YANTAI PROTGEN BIOTECHNOLOGY DEVELOPMENT CO., LTD., BEIJING PROTGEN LTD.Inventors: Yongzhang Luo, Dawei Cui, Yan Fu, Fei Wu, Xiaomin Song, Michuan Li, Guodong Chang, Chuntao Lu
-
Patent number: 9364493Abstract: The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a regulating agent of lipid raft/caveolae-dependent endocytic pathway and some therapeutic agents, such as anti-tumor agents. The invention also relates to a method for screening a regulating agent of lipid raft/caveolae-dependent endocytic pathway capable of enhancing the therapeutic efficacy of anti-tumor agents.Type: GrantFiled: March 28, 2012Date of Patent: June 14, 2016Assignees: Tsinghua University, Beijing Protgen LTD.Inventors: Yongzhang Luo, Yang Chen, Yan Fu, Lin Jia, Guodong Chang
-
Publication number: 20150259432Abstract: The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence, status or metastasis of cancer by detecting plasma Hsp90? having the amino acid sequence of SEQ ID NO:1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.Type: ApplicationFiled: February 13, 2015Publication date: September 17, 2015Applicants: TSINGHUA UNIVERSITY, PROTGEN LTD.Inventors: Yongzhang LUO, Xiaomin SONG, Xiaofeng WANG, Wei ZHUO, Guodong CHANG, Yan FU
-
Publication number: 20150197733Abstract: The present invention discloses a new anti-tumor medicament comprising a mutant of endostatin. The mutant comprises a mutation in the ATP-binding site of endostatin and has a decreased ATPase activity and an increased anti-angiogenesis activity.Type: ApplicationFiled: September 10, 2012Publication date: July 16, 2015Applicants: BEIJING PROTGEN LTD., TSINGHUA UNIVERSITYInventors: Yongzhang Luo, Peng Liu, Xinan Lu, Yang Chen, Yan Fu, Guodong Chang, Daifu Zhou
-
Patent number: 8975030Abstract: The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence, status or metastasis of cancer by detecting plasma Hsp90? having the amino acid sequence of SEQ ID NO:1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.Type: GrantFiled: March 4, 2013Date of Patent: March 10, 2015Assignees: Tsinghua University, Protgen Ltd.Inventors: Yongzhang Luo, Xiaomin Song, Xiaofeng Wang, Wei Zhuo, Guodong Chang, Yan Fu
-
Publication number: 20140335152Abstract: The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a regulating agent of lipid raft/caveolae-dependent endocytic pathway and some therapeutic agents, such as anti-tumor agents. The invention also relates to a method for screening a regulating agent of lipid raft/caveolae-dependent endocytic pathway capable of enhancing the therapeutic efficacy of anti-tumor agents.Type: ApplicationFiled: March 28, 2012Publication date: November 13, 2014Applicants: TSINGHUA UNIVERSITY, BEIJING PROTGEN LTD.Inventors: Yongzhang LUO, Yang CHEN, Yan FU, Lin JIA, Guodong CHANG
-
Publication number: 20140308263Abstract: The present invention discloses a new anti-tumor medicament comprising a mutant of endostatin. The mutant comprises a mutation in the ATP-binding site of endostatin and has a decreased ATPase activity and an increased anti-angiogenesis activity.Type: ApplicationFiled: September 10, 2012Publication date: October 16, 2014Applicants: BEIJING PROTGEN LTD., TSINGHUA UNIVERSITYInventors: Yongzhang Luo, Peng Liu, Xinan Lu, Yang Chen, Yan Fu, Guodong Chang, Daifu Zhou